

## End of Result Set



Generate Collection

L11: Entry 5 of 5

File: DWPI

Jun 10, 1999

DERWENT-ACC-NO: 1998-064335

DERWENT-WEEK: 199929

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Therapeutic composition containing epicatechin and/or theaflavin - and/or (gallate) derivatives, optionally as plant extract, useful as health food, dietary supplement or pharmaceutical, as antioxidant, etc.

## PATENT-ASSIGNEE:

ASSIGNEE

CODE

VITASYN GMBH ENTWICKLUNG &amp; VERTRIEB PHAR

VITAN

PRIORITY-DATA: 1996DE-1027344 (July 1, 1996), 1996DE-2023606 (July 1, 1996)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 29623606 U1	June 10, 1999		000	A61K035/78
DE 19627344 A1	January 8, 1998		007	A61K031/35

## APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE29623606U1	July 1, 1996	1996DE-1027344	Application no.
DE29623606U1	July 1, 1996	1996DE-2023606	
DE19627344A1	July 1, 1996	1996DE-1027344	

INT-CL (IPC): A23 L 1/29; A61 K 31/35; A61 K 35/78

ABSTRACTED-PUB-NO: DE19627344A

## BASIC-ABSTRACT:

A composition (I) contains (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin-3-gallate, (-)-epigallocatechin-3-gallate, theaflavin (TF-1), theaflavin monogallate A (TF-2A), theaflavin monogallate B (TF-2B) and/or theaflavin digallate (TF-3), obtained by extraction from Camellia sinensis L. or by synthesis, in the form of a complete drug, drug components, extracts, individual components, derivatives and/or mixtures.

USE - (I) is useful for the prevention or treatment of oxidative stress, toxic effects due to radical chain reaction damage to biological structures, tumours and their earlier stages, metastasis, radical damage in cytostatic chemotherapy, radical damage radiation therapy or chemotherapy, humoral or cellular immunity diseases (including autoimmune diseases, HIV and AIDS), inhibition of reverse transcriptase of HIV-1 and other HIV types, inflammatory diseases of all types, liver disease, infections (including infection with bacteria, virus, protozoa, virion, prion), arteriosclerosis, lipid metabolism disorders, hyperglycaemia, hypertension, diarrhoea and hypercholesterolaemia; as supportive therapy in weight reduction (medical or cosmetic); for reduction of high serum triglycerides; for improvement of atherogenic index in patients at cardiovascular risk factors; to improve the antioxidant status of patients with renal insufficiency, especially in haemodialysis patients; for the prophylaxis and delaying of premature ageing in all tissues in living conditions associated with premature ageing; and for the prophylaxis of caries (all claimed). The treatment is useful in rheumatic conditions and cancer.

Dosage is 300-1200 mg per day. Administration is oral, enteral, parenteral, rectal, external, intramuscular, subcutaneous, vaginal, sublingual, nasal, buccal, dermal, or intracutaneous.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: THERAPEUTIC COMPOSITION CONTAIN GALLATE DERIVATIVE OPTION PLANT EXTRACT  
USEFUL HEALTH FOOD DIET SUPPLEMENT PHARMACEUTICAL ANTIOXIDANT

ADDL-INDEXING-TERMS:

TUMOUR HIV IMMUNE HYPERTENSION CARIES

DERWENT-CLASS: B02 D13

CPI-CODES: B06-A01; B14-A02; B14-C03; D03-H01T2; D08-A05;

CHEMICAL-CODES:

Chemical Indexing M2 \*01\*

Fragmentation Code

D013 D023 D120 G015 G100 H4 H405 H421 H444 H8  
M1 M113 M280 M320 M412 M431 M511 M520 M531 M540  
M782 M903 M904 P714 P814 Q220

Specific Compounds

19452M

Chemical Indexing M2 \*02\*

Fragmentation Code

D013 D023 D120 G015 G017 G100 H4 H405 H444 H8  
J0 J011 J2 J221 M1 M113 M123 M136 M280 M320  
M412 M431 M511 M520 M532 M540 M782 M903 M904 P714  
P814 Q220

Specific Compounds

13045M

Chemical Indexing M2 \*03\*

Fragmentation Code

D013 D023 D120 G017 G019 G100 H4 H405 H444 H8  
J0 J011 J2 J221 M1 M113 M123 M136 M280 M320  
M412 M431 M511 M520 M532 M540 M782 M903 M904 P714  
P814 Q220

Specific Compounds

07947M

Chemical Indexing M2 \*04\*

Fragmentation Code

D013 D023 D120 G017 G100 H4 H405 H421 H444 H8  
M1 M113 M280 M320 M412 M431 M511 M520 M531 M540  
M782 M903 M904 P714 P814 Q220

Specific Compounds

13044M

Chemical Indexing M2 \*05\*

Fragmentation Code

D013 D019 D023 D029 D120 D199 G023 G036 G230 H4  
H405 H422 H444 H461 H8 J5 J561 M1 M115 M116  
M280 M320 M412 M431 M512 M520 M531 M540 M782 M903  
M904 P714 P814 Q220

Specific Compounds

14561M

Chemical Indexing M2 \*06\*

Fragmentation Code

D013 D019 D023 D029 D120 D199 G017 G019 G023 G036  
G112 G230 H4 H405 H444 H461 H8 J0 J012 J2

J222 J5 J561 M1 M115 M116 M123 M129 M136 M139  
M280 M320 M412 M431 M512 M520 M533 M540 M782 M903  
M904 P714 P814 Q220  
Specific Compounds  
14564M

## Chemical Indexing M2 \*07\*

Fragmentation Code  
D013 D019 D023 D029 D120 D199 G017 G023 G036 G111  
G230 H4 H405 H421 H444 H461 H8 J0 J011 J2  
J221 J5 J561 M1 M115 M116 M123 M136 M280 M320  
M412 M431 M512 M520 M532 M540 M782 M903 M904 P714  
P814 Q220  
Specific Compounds  
14562M

## Chemical Indexing M2 \*08\*

Fragmentation Code  
D013 D019 D023 D029 D120 D199 G017 G023 G036 G111  
G230 H4 H405 H421 H444 H461 H8 J0 J011 J2  
J221 J5 J561 M1 M115 M116 M123 M136 M280 M320  
M412 M431 M512 M520 M532 M540 M782 M903 M904 P714  
P814 Q220  
Specific Compounds  
14563M

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-022479